IQVIA (NYSE:IQV) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of IQVIA (NYSE:IQVFree Report) from a hold rating to a strong-buy rating in a research note released on Thursday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial raised their price target on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Barclays raised their price target on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Finally, Cowen restated a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $236.45.

Get Our Latest Research Report on IQV

IQVIA Trading Down 2.3%

NYSE IQV opened at $198.35 on Thursday. The firm has a market cap of $33.72 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.18 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s 50-day moving average is $189.02 and its 200-day moving average is $168.19. IQVIA has a one year low of $134.65 and a one year high of $237.34.

IQVIA (NYSE:IQVGet Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the firm earned $2.64 EPS. IQVIA’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Institutional investors have recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd boosted its stake in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC raised its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA in the 1st quarter valued at $33,000. Asset Dedication LLC raised its holdings in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares in the last quarter. Finally, Trust Co. of Toledo NA OH acquired a new position in IQVIA in the 2nd quarter valued at $39,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.